<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although identification of <z:mpath ids='MPATH_129'>epithelial dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is critically important because of a significant risk of progression to invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, the diagnosis of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> may be challenging </plain></SENT>
<SENT sid="1" pm="."><plain>Among confounding factors are interobserver variability, tangential sectioning, and severe mucosal <z:mp ids='MP_0001845'>inflammation</z:mp> leading to architectural and cytologic atypia similar to that of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>alpha-methylacyl-<z:chebi fb="3" ids="15346">coenzyme A</z:chebi> racemase (AMACR) is an enzyme involved in beta-oxidation of branched fatty acids and an established marker of <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>It is expressed in colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> but not in <z:mpath ids='MPATH_458'>normal</z:mpath> colonic epithelium suggesting a role in development of gastrointestinal <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We investigated whether expression of AMACR can be used to identify <z:mpath ids='MPATH_589'>dysplasia</z:mpath> of BE and to distinguish it from reactive atypia </plain></SENT>
<SENT sid="5" pm="."><plain>Ninety-six routinely processed biopsy and/or resection specimens (23 negative for <z:mpath ids='MPATH_589'>dysplasia</z:mpath>; 19, low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>; 22, high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>; 16, reactive atypia; and 16, esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) were immunostained using a monoclonal anti-AMACR antibody p504S </plain></SENT>
<SENT sid="6" pm="."><plain>AMACR staining was uniformly negative in the groups negative for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and with reactive atypia </plain></SENT>
<SENT sid="7" pm="."><plain>Only 2 (11%) of 19 specimens with low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> showed positive immunostaning, compared with 14 (64%) of 22 in high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> group </plain></SENT>
<SENT sid="8" pm="."><plain>Of 16 specimens, 12 (75%) showed positive staining for AMACR in the <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> group </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest that AMACR immunoreactivity is moderately sensitive in identification of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in BE and is highly specific in distinguishing high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> from reactive atypia </plain></SENT>
<SENT sid="10" pm="."><plain>Further validation and prospective studies are warranted </plain></SENT>
</text></document>